IGF-1 DES: Mechanism, Dosing, and Clinical Evidence
A guide to IGF-1 DES: how it differs from IGF-1 LR3, what the receptor-binding data show, realistic dosing windows, and when a prescriber might consider it.
A guide to IGF-1 DES: how it differs from IGF-1 LR3, what the receptor-binding data show, realistic dosing windows, and when a prescriber might consider it.
A guide to peptide purity testing standards, FDA 503A compounding rules, sterility requirements, and storage stability. Learn how to verify that your peptide therapy is safe, potent, and legally dispensed.
A guide to the FDA regulatory status of BPC-157, why compounding pharmacies can no longer legally dispense it, what the evidence actually shows, and what alternatives exist for patients.
BPC-157 injections can cause local redness, swelling, and pain at the injection site. Learn why this happens, how to reduce it, and which peptide alternatives carry a lower risk of injection-site reactions.
Understand CJC-1295 study design, DAC terminology, GH and IGF-1 findings, and why early research does not establish a standard titration or stacking schedule.
A complete clinical guide to monitoring BPC-157 (pentadecapeptide) use in older adults ages 50 to 64, covering baseline labs, cardiovascular risk, polypharmacy interactions, and cycle management.
A prescriber-level monograph covering the copper peptides drug class: mechanisms, pharmacology, clinical evidence, dosing, safety, and comparisons with prototype GHK-Cu. Includes citations to primary literature.
A physician-level guide to copper peptide pharmacology, GHK-Cu dosing protocols, titration schedules, tapering strategies, and safety monitoring for skin and hair regeneration.
A clinical comparison of ipamorelin acetate and ibutamoren (MK-677), covering mechanism, dosing, side effects, and how to switch between them safely.
Step-by-step epitalon self-injection technique, mechanism of action, dosing protocols, and safety considerations. Written by the HealthRX.com medical team and backed by primary research.
A physician-level review of ipamorelin acetate and cancer risk, covering IGF-1 biology, preclinical data, clinical evidence gaps, and how to screen patients before prescribing.
An evidence-based guide to ipamorelin acetate use during pregnancy and breastfeeding, covering mechanism, fetal risk, lactation transfer, and clinical alternatives.
How to read a C-peptide result at every age, from childhood through your 70s. Includes typical reference ranges, clinical use in T1D vs T2D diagnosis, and what low or high values may mean for metabolic health.
Everything you need to know about traveling and daily life with Egrifta (tesamorelin) for HIV-associated lipodystrophy, storage, TSA rules, injection timing, and what real patients report.
A complete guide to Sermorelin's legal status in Massachusetts, covering FDA rules, 503A/503B compounding, state pharmacy board oversight, and how to get a legitimate prescription.
A guide to Sermorelin's legal status in Massachusetts, covering FDA scheduling, 503A/503B compounding rules, the Massachusetts Board of Registration in Pharmacy, and how patients can lawfully obtain a prescription.
A guide to Sermorelin's legal status in Tennessee, covering FDA compounding rules, 503A/503B pharmacy law, Tennessee Board of Pharmacy regulations, and how to obtain a legitimate prescription.
A guide to TB-500's legal status in Arizona, covering FDA regulations, 503A/503B compounding rules, state pharmacy board rules, and how to access TB-500 legally.
A complete guide to TB-500's legal status in Oregon, covering FDA regulations, the 503A/503B compounding framework, the Oregon Board of Pharmacy, and what patients need to know before seeking a prescription.
A complete guide to TB-500's legal status in Tennessee, covering FDA regulations, 503A/503B compounding pharmacy rules, state pharmacy board requirements, and how patients can access thymosin beta-4 peptide legally through a licensed provider.
A complete guide to Egrifta (Tesamorelin) legal status in Louisiana, covering FDA approval, federal scheduling, 503A/503B compounding rules, Louisiana pharmacy board regulations, and how to obtain a legitimate prescription.
A complete guide to the legal status of Thymosin Alpha-1 in Colorado, covering FDA bulk-drug lists, 503A/503B compounding pharmacy rules, state pharmacy board requirements, and how to obtain a legitimate prescription.
A complete guide to FDA warning letters, USP <797> sterility standards, PCAB accreditation, and practical buyer guidance for sermorelin compounded peptides.
A complete guide to BPC-157's FDA regulatory status in 2026, including the 503A/503B compounding ban, TB-500 status, how to verify a peptide COA, and what the 'research use only' label actually means.
A breakdown of peptide prescription costs by compound, covering BPC-157, TB-500, GHK-Cu, CJC-1295/Ipamorelin, and insurance coverage realities for 2026.
A complete regulatory and clinical overview of BPC-157: its current FDA status, compounding pharmacy classification, ongoing research pipeline, safety data, and what next-generation formulations may look like.
A guide to ipamorelin's regulatory status worldwide, including FDA compounding restrictions, EMA standing, and what clinicians and patients need to know before prescribing or obtaining this growth hormone secretagogue.
A comprehensive review of Egrifta (tesamorelin) regulatory history, patent disputes, FDA labeling requirements, and post-market safety surveillance, with primary-source citations throughout.
A data-informed look at TB-500 (thymosin beta-4 active fragment) user satisfaction trends across Reddit, review platforms, and clinical context. Includes bias analysis, real results, and prescriber guidance.
Evidence-based sermorelin acetate dosing for adults aged 30, 49, including starting doses, titration schedules, injection technique, monitoring, and safety considerations reviewed by HealthRX.com physicians.
A clinician-level history of sermorelin acetate: how it was discovered, how it works, the key trials that shaped its use, and why it moved from FDA-approved drug to 503A compounding pharmacy staple.
Numbness during peptide therapy (GLP-1s, BPC-157, TB-500, semaglutide, tirzepatide) has identifiable causes. Learn which labs to order, what the findings mean, and when to escalate care.
Tesamorelin interaction evidence separating label-supported medicine interactions from unsupported fasting, alcohol, vitamin, herb, and supplement rules.
Complete guide to Egrifta (tesamorelin) storage conditions, reconstitution stability, shelf life, and mechanism of action. Reviewed by board-certified physicians with primary-source citations.
A clinical overview of BPC-157 pentadecapeptide in autoimmune disease contexts, covering mechanisms, evidence, risks, and prescribing considerations for 2024.
A guide to AOD-9604's federal and Arizona-specific legal status, compounding pharmacy pathways, prescription requirements, and what patients need to know before seeking access in 2024.
A guide to AOD-9604's legal status in California, covering FDA scheduling, the 503A/503B compounding framework, state pharmacy board rules, and what a compliant prescription pathway looks like in 2024.
A guide to AOD-9604's federal regulatory status, Louisiana-specific pharmacy law, compounding pathways under 503A/503B, and what patients need to do to access the peptide legally in 2024.
A detailed breakdown of AOD-9604's federal and Massachusetts legal status, how the FDA bulk compounding list affects access, and what patients need to know before seeking a prescription in 2024.
A breakdown of BPC-157's federal regulatory status, Alabama pharmacy law, and the only legal access paths available to Alabama residents in 2024.
BPC-157 occupies a legal gray zone in Alabama. Learn what FDA policy, 503A/503B compounding rules, and Alabama pharmacy law actually say about obtaining BPC-157 in 2024.
A guide to BPC-157's federal and Florida legal status, the FDA bulks list, 503A/503B compounding rules, and how to get a legitimate prescription in 2024.
A complete breakdown of BPC-157's legal status in Kentucky, covering FDA scheduling, the 503A/503B compounding framework, the Kentucky Board of Pharmacy rules, and what patients and clinicians need to know before obtaining or prescribing BPC-157 in 2024.
A detailed breakdown of BPC-157's federal and Washington State legal status, including FDA regulatory classification, 503A/503B compounding rules, and what patients and clinicians need to know in 2024.
A guide to the federal and North Carolina legal status of PT-141 (Bremelanotide), how to get a legal prescription, and what compounding rules apply in 2024.
A guide to the federal and Texas-specific legal status of PT-141 (Bremelanotide), how to obtain a lawful prescription, and what compounding rules apply in 2024.
A guide to the federal and Virginia-specific legal status of PT-141 (Bremelanotide), including how to obtain a legal prescription and what compounding rules apply in 2024.
A guide to the federal and California legal framework for Egrifta (tesamorelin): FDA approval status, 503A/503B compounding rules, how to get a valid prescription, and what telehealth patients need to know in 2024.
A complete guide to the federal and Oregon-specific legal status of Egrifta (Tesamorelin), how to get a prescription, and what patients and clinicians need to know in 2024.
A complete guide to the federal and Illinois-specific legal framework for Thymosin Alpha-1, covering FDA status, 503A/503B compounding, prescription pathways, and how to get it legally in 2024.
A guide covering the federal and Texas-specific legal framework for Thymosin Alpha-1, including FDA bulk-drug status, 503A/503B compounding rules, prescription requirements, and how patients can access it legally in 2024.
Understand the regulatory difference between research-only and medical-grade GHK-Cu, how to verify pharmacy quality through HPLC, sterility, and endotoxin testing, and what FDA guidance means for buyers in 2024.
Evidence-based guide to AOD-9604 (HGH fragment 176-191) dosing considerations for Black and African ancestry patients, covering pharmacogenomics, metabolic differences, and clinical monitoring.
Clinical review of AOD-9604 (HGH fragment 176-191) safety considerations for Black and African ancestry patients, covering pharmacogenomics, dosing, metabolic context, and monitoring gaps.
Evidence review of GHK-Cu (copper tripeptide) efficacy in Black and African ancestry populations, covering pharmacogenomic factors, melanin-rich skin penetration, G6PD prevalence, and dosing guidance.
Evidence-based review of MOTS-c mitochondrial peptide efficacy differences in Black and African ancestry populations, including pharmacogenomic factors, dosing considerations, and clinical gaps.
Can you take AOD-9604 (HGH fragment 176-191) with metformin? Review the pharmacokinetic and pharmacodynamic interaction profile, monitoring recommendations, and dose-adjustment considerations.
Is it safe to combine GHK-Cu (copper tripeptide) with diphenhydramine? Review the pharmacokinetic and pharmacodynamic interaction profile, monitoring recommendations, and patient counseling points.
Can you take GHK-Cu with progesterone HRT? A guide covering pharmacokinetic and pharmacodynamic overlap, monitoring recommendations, and patient counseling for copper tripeptide GHK-Cu used alongside progesterone hormone replacement therapy.
Can you take MOTS-c with pregabalin? Review the pharmacokinetic and pharmacodynamic interaction profile, monitoring recommendations, and dose-adjustment guidance for combining MOTS-c mitochondrial peptide with pregabalin.